NASDAQ$AKBA
Akebia Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Akebia reported financial results for the first quarter ended March 31, 2024.
Akebia Therapeutics reported total revenues of $32.6 million for Q1 2024, with net product revenues of $31.0 million from Auryxia. The company's net loss was $18.0 million. They are preparing for the launch of Vafseo in January 2025.
- Vafseo (vadadustat) tablets FDA approved on March 27, 2024, with launch activities underway and availability expected in January 2025.
- Auryxia (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, and Akebia expects 2024 Auryxia net product revenue growth versus 2023.
- Akebia plans to submit its application for Transitional Drug Add-on Payment Adjustment (TDAPA) for Vafseo in June and expects TDAPA designation in January 2025.
- Akebia signed an amendment to its License Agreement with Vifor International Ltd. to modify the method of repayment of its working capital fund through tiered royalties based upon Akebia’s sales of Vafseo, significantly simplifying the repayment terms.
Headline financials
Revenue & EPS history
Akebia · Revenue · Quarterly
$32.6M
Revenue by segment
Akebia · $40.1M total across 2 segments · Q1 2023
- Auryxia$34.8M-15.9%86.8%
- License & other revenue$5.3M-73.8%13.2%
Forward guidance
Akebia expects Auryxia net product revenue growth in 2024 versus 2023 and believes its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including a U.S. Vafseo launch, for at least the next two years.
Tailwinds
- Auryxia net product revenue growth is expected in 2024 versus 2023.
- Existing cash resources and cash from operations are expected to fund the current operating plan for at least the next two years.
- Cash runway includes the U.S. Vafseo launch.
- Vafseo launch activities are underway.
- Akebia is accelerating contracting discussions with dialysis organizations with a goal to ensure broad access to Auryxia.
Headwinds
- The commercial availability of Vafseo is not expected until January 2025.
- The market potential and acceptance of Vafseo are subject to uncertainty.
- The competitive landscape for Auryxia and Vafseo could impact revenue.
- Decisions made by health authorities, such as the FDA, could affect regulatory filings.
- Manufacturing, supply chain, and quality matters could have potential consequences.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-2.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
41%
19 / 46 earnings
Positive
+34.4%
Q1 2020
Best reaction
-22.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -20.3% | -20.3% | -36.7% | |
| Q4 2025 | +9.9% | +0.8% | +10.7% | |
| Q3 2025 | -18.4% | -18.1% | -20.1% | |
| Q1 2025 | +6.6% | +0.8% | +61.4% | |
| Q4 2024 | -12.4% | +32.1% | -14.5% | |
| Q3 2024 | -3.0% | -2.5% | +2.5% | |
| Q2 2024 | +0.0% | +20.7% | +21.6% | |
| Q1 2024 | -13.6% | -12.1% | -24.3% | |
| Q4 2023 | +20.6% | +29.8% | +3.5% | |
| Q3 2023 | -16.5% | -15.3% | +3.7% | |
| Q2 2023 | +10.4% | +12.0% | -5.6% | |
| Q1 2023 | -3.7% | +3.7% | +17.4% | |
| Q4 2022 | -22.4% | -33.7% | -47.6% | |
| Q3 2022 | +1.9% | +2.6% | +9.0% | |
| Q2 2022 | +1.0% | +3.6% | -2.8% | |
| Q1 2022 | +11.2% | +16.6% | +15.6% | |
| Q4 2021 | +13.4% | +12.0% | -66.8% | |
| Q3 2021 | -12.3% | -14.4% | -24.6% | |
| Q2 2021 | +10.5% | +6.5% | +22.2% | |
| Q1 2021 | +2.6% | +10.6% | +17.9% | |
| Q4 2020 | -19.2% | -17.5% | -26.2% | |
| Q3 2020 | -7.4% | +0.8% | +19.8% | |
| Q2 2020 | -6.4% | -4.1% | -75.9% | |
| Q1 2020 | +34.4% | +38.3% | +40.6% | |
| Q4 2019 | -13.8% | -27.0% | -13.0% | |
| Q3 2019 | -9.6% | -8.2% | +73.5% | |
| Q2 2019 | +20.5% | +22.4% | +11.2% | |
| Q1 2019 | +1.5% | -0.7% | -26.8% | |
| Q4 2018 | -0.9% | +2.7% | -15.3% | |
| Q3 2018 | +10.3% | -4.2% | +5.0% | |
| Q2 2018 | -18.1% | -22.1% | -20.8% | |
| Q1 2018 | +0.7% | +11.0% | +10.5% | |
| Q4 2017 | -10.6% | -12.6% | -28.9% | |
| Q3 2017 | -12.6% | -12.8% | -8.5% | |
| Q2 2017 | +6.8% | +9.4% | +26.0% | |
| Q1 2017 | -2.3% | +2.2% | +8.2% | |
| Q4 2016 | -12.6% | -9.3% | -11.1% | |
| Q3 2016 | +10.6% | +14.1% | +9.9% | |
| Q2 2016 | -9.6% | -7.4% | -3.8% | |
| Q1 2016 | -8.8% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +3.3% | — | — | |
| Q3 2014 | -3.2% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro